127 related articles for article (PubMed ID: 37888775)
1. Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab.
Beigneux Y; Louapre C; Bihan K; Roux T; de Paz R; Lubetzki C; Maillart E
Mult Scler; 2024 Jan; 30(1):131-133. PubMed ID: 37888775
[TBL] [Abstract][Full Text] [Related]
2. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
3. Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study.
Rigal J; Biotti D; Lépine Z; Ciron J
Rev Neurol (Paris); 2022 Mar; 178(3):253-255. PubMed ID: 34579948
[TBL] [Abstract][Full Text] [Related]
4. Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report.
Maniscalco GT; Allegorico L; Di Battista ME; Annunziata M; Salvatore S; Manzo V
Neurol Sci; 2021 Sep; 42(9):3933-3935. PubMed ID: 34170432
[No Abstract] [Full Text] [Related]
5. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Wolach O; Bairey O; Lahav M
Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
[TBL] [Abstract][Full Text] [Related]
6. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.
Zanetta C; Robotti M; Nozzolillo A; Sangalli F; Liberatore G; Nobile-Orazio E; Filippi M; Moiola L
J Neurol Sci; 2020 Feb; 409():116603. PubMed ID: 31811986
[No Abstract] [Full Text] [Related]
7. Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.
Shimony S; Bar-Sever E; Berger T; Itchaki G; Gurion R; Yeshurun M; Lahav M; Raanani P; Wolach O
Leuk Lymphoma; 2021 Dec; 62(12):2921-2927. PubMed ID: 34284690
[TBL] [Abstract][Full Text] [Related]
8. Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report.
Rauniyar R; Rauniyar R; Agrawal A; Yadav S; Avula S
Clin Case Rep; 2022 Jan; 10(1):e05299. PubMed ID: 35079395
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.
Besada E; Koldingsnes W; Nossent J
QJM; 2012 Jun; 105(6):545-50. PubMed ID: 22301823
[TBL] [Abstract][Full Text] [Related]
10. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab.
Alba Suárez EM; Tallón Barranco A; Puertas Muñoz I; Chamorro Hernández B; Robles Marhuenda Á
Neurologia (Engl Ed); 2023 Sep; 38(7):463-466. PubMed ID: 37659836
[TBL] [Abstract][Full Text] [Related]
11. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas.
Tesfa D; Sander B; Lindkvist H; Nilsson C; Kimby E; Hägglund H; Wahlin BE; Klimkowska M; Palmblad J
Med Oncol; 2021 May; 38(6):70. PubMed ID: 34003398
[TBL] [Abstract][Full Text] [Related]
12. Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.
Monaco WE; Jones JD; Rigby WF
Clin Rheumatol; 2016 Oct; 35(10):2457-62. PubMed ID: 27209045
[TBL] [Abstract][Full Text] [Related]
13. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
Nitta E; Izutsu K; Sato T; Ota Y; Takeuchi K; Kamijo A; Takahashi K; Oshima K; Kanda Y; Chiba S; Motokura T; Kurokawa M
Ann Oncol; 2007 Feb; 18(2):364-9. PubMed ID: 17079695
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.
Parodis I; Söder F; Faustini F; Kasza Z; Samuelsson I; Zickert A; Svenungsson E; van Vollenhoven RF; Malmström V; Wermeling F; Gunnarsson I
Lupus; 2018 Aug; 27(9):1470-1478. PubMed ID: 29783918
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
Zonozi R; Wallace ZS; Laliberte K; Huizenga NR; Rosenthal JM; Rhee EP; Cortazar FB; Niles JL
Arthritis Rheumatol; 2021 Feb; 73(2):347-354. PubMed ID: 32892495
[TBL] [Abstract][Full Text] [Related]
16. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia after rituximab treatment: new insights on a late complication.
Wolach O; Shpilberg O; Lahav M
Curr Opin Hematol; 2012 Jan; 19(1):32-8. PubMed ID: 22080846
[TBL] [Abstract][Full Text] [Related]
18. Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: A retrospective case series and a systematic review of reported cases.
Rossi L; Dinoto A; Bratina A; Baldini S; Pasquin F; Bosco A; Sartori A; Manganotti P
Mult Scler Relat Disord; 2022 Dec; 68():104090. PubMed ID: 35994977
[TBL] [Abstract][Full Text] [Related]
19. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab.
Alba Suárez EM; Tallón Barranco A; Puertas Muñoz I; Chamorro Hernández B; Robles Marhuenda Á
Neurologia (Engl Ed); 2021 Mar; ():. PubMed ID: 33726971
[TBL] [Abstract][Full Text] [Related]
20. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
